Cancer Segment Likely First Market For Roche’s SynergysDx Program
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics is anticipating that the drive to commercialize pharmacogenomic technology will create a need for coordinated drug and diagnostic premarket efforts, triggering increased demand for development partnerships between the two sectors
You may also be interested in...
FDA Pharmocogenomic Data Guidance To Be Finalized By Year-End
FDA will issue a final guidance on pharmacogenomic data submissions later this year, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, told the Biotechnology Industry Organization annual meeting in San Francisco
FDA Pharmocogenomic Data Guidance To Be Finalized By Year-End
FDA will issue a final guidance on pharmacogenomic data submissions later this year, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, told the Biotechnology Industry Organization annual meeting in San Francisco
Diagnostic Makers Seek Clarification On Biomarker Validation Standards
FDA should elucidate biomarker terminology in finalizing its guidance on pharmacogenomic data submissions, Genzyme says in comments to the agency